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A B S T R A C T
Background. Although breakthrough pain (BTP; pain flares interrupting well-controlled baseline
pain) is common among patients with cancer, its prevalence, characteristics, and impact on health-
related quality of life (HRQOL) are poorly understood in ethnic minorities.
Methods. This comparative study examines ethnic and gender differences in BTP characteristics
and impact on HRQOL. Patients with stage III or IV cancer of the breast, prostate, colorectal, or
lung, or stage II–IV multiple myeloma with BTP completed surveys (upon initial assessment, 3
months, and 6 months) assessing consistent pain, BTP, depressed affect, active coping ability, and
HRQOL.
Results. Respondents (N = 96) were 75% white, 66% female with a mean age of 56  10 years. All
subjects experienced significant psychological distress, but there were no racial differences in
depression prevalence. Minorities reported significantly greater severity for consistent pain at its
worst (P = 0.009), least (P  0.001), on average (P = 0.004), and upon initial assessment (P = 0.04) as
well as greater severity for BTP at its worst (P = 0.03), least (P = 0.02), and at initial assessment
(P = 0.008). Although minorities reported more flare types (3.0 vs 1.8, P = 0.001), there were no
significant ethnic differences in the duration, quality, or location of pain flares. Minorities consis-
tently reported poorer outcomes on each HRQOL subscale (physical, role, emotional, cognitive,
and social functioning) measured, although not statistically significant, as well as poorer QOL
symptom control (P = 0.08) including lower dyspnea control (P = 0.002).
Conclusions. Overall, minorities experienced greater consistent and breakthrough pain as well as
poorer HRQOL. These data suggest further health care disparities in the cancer and pain experi-
ence for minorities.
Key Words. Breakthrough Pain; Cancer Pain; Gender; Health Care and Health Policy; Physician
Variability; Pain Management; Racial and Ethnic Disparities
Introduction
Cancer pain (i.e., pain associated with cancer orits treatment) is common and significantly
impairs health and quality of life (QOL). Pain is
experienced by more than 60% of patients with
cancer [1] and attributed to direct effects of the
neoplasm, therapeutic interventions, and syn-
dromes unrelated to the disease process [2]. Break-
through pain (BTP; a transitory flare of moderate
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to severe pain, interrupting mild background pain
being controlled by a stable analgesic regimen) is a
common problem among patients with cancer and
may lead to complicated clinical problems [3].
When BTP occurs, it may indicate more severe
pain syndromes in patients with cancer while also
predicting an inadequate response to analgesics
[4]. Previous observational studies describing
BTP’s characteristics and treatment in the cancer
population vary widely with prevalence estimates
ranging from 19% [5] to 93% [6]. Zeppetella
et al.’s study of patients with cancer admitted to a
hospice facility found 89% presented with BTP
[7]. Portenoy et al. described BTP’s quality and
characteristics while distinguishing it from other
pain syndromes [7–9]. The existing literature indi-
cates variability in BTP flares (lasting from
seconds to hours) and the unpredictable quality
(often described as sharp, dull, achy, lancinating,
or burning) [7].
Pain is a feared symptom, and patients with
cancer often believe it is a sign that their cancer
has worsened [10,11]. Most patients with cancer
attribute their BTP to tumor location and growth,
while some believe that it is due to cancer treatment
or causes unrelated to their disease process.
Patients commonly report BTP occurs following a
particular movement or at the end of a medication
course (often referred to as end-of-dose failure) [9].
BTP’s unpredictable onset and diverse pathophysi-
ology pose unique challenges while yielding vari-
ability in how physicians manage BTP [9]. It is
commonly treated with “rescue doses” of analgesics
(including opioids) used for managing chronic
cancer pain [9]. A clinically significant pain
syndrome, BTP also impacts health-related
(HRQOL) and mental well-being. When com-
pared with individuals without cancer, patients with
cancer have an increased prevalence of depressed
mood and psychological distress resulting in
decreased personal well-being and HRQOL [12].
Additionally, patients experiencing BTP have more
psychological distress and lower HRQOL than the
general cancer population [8]. Patients with cancer
with BTP experience significantly more functional
impairment, higher anxiety, and an increased
prevalence of depressed mood than patients with
cancer without BTP. Although many researchers
have contributed to an understanding of BTP’s
characteristics and consequences, most studies fail
to explore racial or gender differences [3].
Disparities in health and health care are well
documented and remain a significant public health
problem [13]. The Institute of Medicine’s reports
on health and health care disparities also docu-
ment the unequal burden of cancer [13,14] while
devoting minimal attention to pain. Overall,
blacks have higher incidence and mortality rates
for colorectal, lung, prostate, and breast cancer
whites [14–19]. In addition, disparities in the
prevalence, severity and treatment for all types of
pain as well as structural barriers to pain care exist
[20–22]. Minorities have a higher prevalence and
more severe pain than non-Hispanic whites
[23–26]. They are also less likely to have their pain
complaints adequately assessed or documented in
their medical chart [27]. Additionally, minority
patients disproportionately receive inadequate
analgesic therapy for their cancer pain and tend to
report less satisfaction with pain treatment as well
as less pain relief from pain medication when com-
pared with non-Hispanic whites [10]. Even when
treated, minorities experience additional barriers
compared with non-Hispanic whites in accessing
pain medications with pharmacies located in
minority neighborhoods less likely to maintain
adequate opioid analgesic supplies [28]. Likewise,
the pain complaints of women receive less atten-
tion [29], and they are also at risk for suboptimal
pain treatment than men. Overall studies attempt-
ing to examine gender-based differences in cancer
pain are rare and reveal few differences in the
severity of consistent pain. Although there is
support for disparities in cancer pain treatment
[30], gender-based differences in BTP have not
been examined.
While there is evidence for racial and ethnic
disparities in acute, chronic, and cancer pain care,
previous research has not addressed potential dis-
parities in BTP characteristics or QOL outcomes.
We hypothesized that minorities with advanced
cancer experienced greater consistent pain, more
BTP episodes, and had worse HRQOL than
whites. The current study seeks to enhance the
existing literature by comparing BTP characteris-
tics and QOL in ethnically diverse men and
women. Additionally, this study sought to assess
the impact of ethnicity or gender on BTP,
HRQOL, and mental health.
Methods
Participants
Approval for this study was granted by the Uni-
versity of Michigan Health System Institutional
Review Board (IRB) and the IRB Boards of the
cooperating cancer centers. Written informed
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consent was obtained from each subject upon
study enrollment. The study involved collecting
data from patients with cancer experiencing BTP
with stage III or IV breast, prostate, colorectal
or lung cancer, or stage II, III, or IV multiple
myeloma. Subjects were identified at four urban
outpatient cancer centers and through the Uni-
versity of Michigan Cancer Registry. English-
speaking black, white, Hispanic, Arabic, and
Native American patients between 18 and 75 years
old were recruited for study participation. Only
patients reporting BTP and receiving around-the-
clock analgesic therapy for cancer pain were
included in the study. An Eastern Cooperative
Oncology Group Performance Status of 2 (no
more than 50% of the day spent in bed) was
required for inclusion such that highly impaired
people were excluded from participating in the
study. People 75 years old were excluded as their
pain could be caused by other comorbid condi-
tions. Medications and pain data were collected
from participants upon recruitment.
Measures
Sociodemographics were assessed at screening (age in
years as calculated from birth date, self-identified
race, gender) and in the baseline survey. Marital
status (never married, married, divorced, sepa-
rated, widowed), education (6th grade, >6th
grade but did not finish high school, high school
diploma or equivalent, some college/trade school,
college graduate or equivalent, graduate or profes-
sional school after college), employment (full-time
employed, part-time employed, retired, voluntar-
ily unemployed, involuntarily unemployed), and
household income ($9999 or less, $10,000–
30,000, $30,001–100,000, $100,001) were all
categorical variables. Cancer type and stage were
also collected at screening and confirmed with the
clinical database from the participating institution.
The Brief Pain Inventory (BPI) assessed pain
severity and interference with normal physical and
emotional functioning [31]. Items determined
pain severity (pain at worst, least, average, and
right now), pain-related interference (general,
mood, walking, work, relationships, sleep, life
enjoyment), pain characteristics (timing, duration,
quality, cause), pain location (via two drawings of
the body with instructions to shade areas with
pain), medications, pain medication effectiveness,
and an open-ended item regarding what actions
relieved pain. Characteristics, location, pain medi-
cation effectiveness (0% to 100%), and a dummy
variable for any activity effectively alleviating some
portion of pain (0 = nothing helps, 1 = something
can be performed to lessen pain) were used in
analyses. The BPI severity items were used for
both consistent and breakthrough pain with the
following definitions preceding each section:
“Your everyday, consistent pain is the pain for
which your doctor(s) has prescribed pain medica-
tion(s) on a set daily regimen (for example, every
4–6 hours)” and “During periods of relatively con-
sistent pain or periods that were relatively pain-
free, you may have also experienced temporary
flares of pain or pain attacks.” Internal reliabilities
for the items were 0.90 and 0.83, respectively, for
the consistent and breakthrough pain scales. The
remaining BPI items were asked in relation to
consistent pain.
The Center for Epidemiological Studies Depression
Scale (CES-D) assessed depressed affect. We
dropped the four positively worded items from the
original 20-item survey because factor analysis
showed that the items do not accurately predict
negative effect when reversed as confirmed in
the literature [32,33]. The ordinal values of the
remaining 16 items were summed and weighted to
calculate an overall score comparable to the pub-
lished scale range (0–60); scores >15 indicated
severe psychological distress and depression.
Internal consistency for the 16-item CES-D was
consistent with published values (a = 0.91) [32].
The John Henryism Active Coping Scale (JHACS)
evaluated John Henryism, a high output active
coping strategy characterized by protracted strug-
gles against seemingly insurmountable obstacles.
The construct was originally reported among
aging African Americans and is correlated with
high blood pressure and bodily pain. The sum
score of 12 Likert-type items was calculated
(1 = completely false; 5 = completely true; 60 =
maximum active coping score). Internal consis-
tency (a = 0.87) of the JHACS was higher than
previously published values [34].
The Barriers Questionnaire (BQ-II) assessed bar-
riers in patient attitudes toward pain management
and treatment. The BQ-II questionnaire has four
separate subscales: physiological effects, fatalism,
communication, and harmful effects [35]. Mean
scores were calculated for each set of Likert-type
subscales; fatalism items were reverse scored
before analysis. The internal consistency of BQ-II
subscales ranged from a = 0.60 to 0.91. Only the
fatalism subscale had a reliability value below its
previously published value of a = 0.79 [35]; in this
sample, the reliability value was a = 0.60. Our
small sample size and the few questions on the
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subscale may account for the difference in reli-
abilities, or it may be, as with the CES-D items,
that some items have different meaning to patients
with cancer.
The European Organization for the Research and
Treatment of Cancer survey (EORTC QLQ-C30)
assessed HRQOL [36]. Five QOL functioning
domains (physical, role, cognitive, emotional, and
social) and eight symptom-control domains
(fatigue, pain, nausea, vomiting, dyspnea, anor-
exia, diarrhea, and constipation) were evaluated
(frequency during the past week) for their contri-
bution to QOL. Additional measures assessed
financial concerns, global health, and overall
QOL. All scores were linearly transformed to a
0–100 scale. Internal consistency of the EORTC
subscales (a = 0.71–0.91) was higher than previ-
ously published results [36].
Pain Management Measures
Several pain management measures were com-
puted: 1) pain medication potency; 2) total
number of medications taken; and 3) adequacy of
pain management via the Pain Management Index
(PMI). Using the World Health Organization
guidelines for pain treatment, the PMI was com-
puted by using a combination of patients’ pain
severity scores at worst during the past week and
their current analgesic medication potency. The
medicines were classified into 38 classes by three
medical staff (two anesthesiologists and one
PharmD) and then collapsed into four groups
based on their analgesic function: 0 = nonanalge-
sic; 1 = nonopioid analgesic; 2 = weak opioid;
3 = strong opioid. Using these categories, an ad
hoc procedure was used to classify patients’ treat-
ment into the identical four drug potency catego-
ries yielding the drug potency variable.
The pain severity score collected from the
Mean BPI pain severity scale was collapsed into
four categories: 0 = absence of pain (BPI sever-
ity  0.9); 1 = mild pain (BPI severity = 1.0–3.9);
2 = moderate pain (BPI severity = 4.0–7.9); and
3 = severe pain (BPI severity = 8.0–10.0). The
PMI is the difference between the analgesic
potency and the categorized pain level and ranges
from -3 to +3. This ordinal variable was also used
in its categorical form (0 = inadequate analgesic
therapy [PMI = -3 to 0], 1 = adequate analgesic
therapy [PMI = +1 to +3]).
Statistical Analysis
Descriptive statistics were calculated by using
SPSS (SPSS Inc., Chicago, IL) 14.0. Analysis of
variance (anova) and chi-square analysis were
used. Because of the limited sample size, findings
with a two-tailed probability of type I error of
P  0.10 are reported to determine differences
between whites and minorities and between men
and women in sociodemographics, pain character-
istics, and experiences, and for each QOL measure
examined. Multiple analysis of variance (manova)
was used to examine differences between whites
and minorities and between men and women in
overall consistent pain, BTP severity, QOL func-
tioning, and QOL symptom control, and the
BQ-II subscales as the subscales for these mea-
sures are highly correlated. Correlations were also
examined between consistent and breakthrough
pain variables and other variables. anova and
manova techniques are relatively robust in terms
of assumptions of normality. Additionally, for the
36 continuous or ordinal variables used in the
analyses, only 1 had a skewness of >2 (number of
pain sites). Most (83%) variables had skewness of
1, including all BPI subscales and all the EORTC
subscales except nausea and diarrhea. The com-
bined measures were all normally distributed. Rec-
ognizing that inter- and intrarace variability exists
for all races, a post hoc analysis was performed to
verify that the results would not differ if compari-
sons were made for whites vs blacks (the only sub-
group large enough for comparison).
Results
Demographics
Ninety-six subjects (blacks [N = 19], whites
[N = 68], Hispanic [N = 3], Arabic [N = 2], and
Native Americans [N = 4], including 1 biracial
person counted in both categories) completed the
baseline survey (71% white [24–75 years, N = 68],
29% minority [30–75 years, N = 28], 66% female).
This racial breakdown is consistent with Michi-
gan’s population breakdown overall. There were
no significant differences between the white and
minority sample in age, sex, or education. There
were significant differences in marital status
between the two groups, with whites more likely to
be married (73% vs 29%) and less likely to be
divorced (19% vs 33%) than minorities (P = 0.001).
There were also differences in annual household
income, with whites more likely to fall into the
high-income group ($100,000) than minorities
(P = 0.04). Women were significantly less likely
than men to be married (50% vs 84%, P = 0.01),
and there is a trend for women to be in
Montague and Green552
lower-income groups (P = 0.06). Table 1 provides
additional sociodemographic information for the
sample.
Cancer Differences
Although there were no significant differences
between whites and minorities in primary cancer
diagnosis location, there was a trend level differ-
ence in primary cancer stage (P = 0.09). Compared
with minorities, whites had a higher frequency of
stage IV cancer (whites = 43%, minorities = 29%)
and a lower frequency of stage II cancer
(whites = 2.8%, minorities = 16.7%). Although
the differences were not statistically significant, it
appears that the mean subject age at first primary
cancer diagnosis may be different between whites
and minorities for breast cancer and multiple
myeloma. In both instances, minorities were diag-
nosed at younger ages. Women were more likely
to have a diagnosis of breast cancer, but, when
breast cancer is removed from the diagnostic spec-
trum, there are no differences by gender in preva-
lence of other cancers.
Consistent Pain
The most common pain locations were nonmid-
line back (36%), spine (31%), and legs (28%).
Although there were no significant differences in
the number of pain locations, minorities experi-
enced pain more often than whites in the non-
midline back (54% vs 29%, P = 0.03), upper non-
midline back (32% vs 15%, P = 0.05), lower
nonmidline back (36% vs 12%, P = 0.006), arm
and shoulder (32% vs 16%, P = 0.08), and head
(14% vs 1%, P = 0.01). Women experienced
more spine pain than men (37% vs 18%,
P = 0.06).
Minorities reported significantly higher pain
scores for consistent pain than whites (multivariate
F = 5.49; P = 0.001). Minorities also had signifi-
cantly higher scores on the interference scales
(multivariate F = 2.36; P = 0.03) than whites. Con-
sistent pain and pain interference were not sta-
tistically different by gender, although further
examination shows that, in every case, the mean
interference was higher for women. Figure 1 shows
mean scores on the four consistent pain measures
by ethnicity. Table 2 shows consistent pain, BTP,
and pain interference by race/ethnicity and gender.
The mean PMI of -1.01 suggests that most subjects
were prescribed adequate pain medications
(range = -3 to +3; negative numbers reflecting
medication stronger than pain strength and posi-
tive numbers reflecting pain stronger than medica-
tion). When PMI was examined as a continuous
variable, there were no ethnic or gender differences
in medication strength or subject-reported consis-
tent pain relief received from medication (62%
relieved overall). Further examination of the
dummy variable for “adequate” vs “inadequate”
medication showed that only women (N = 6) were
prescribed inadequate pain medication, a trend
level difference (P = 0.07). Pain interference was
also a significant issue for subjects with mean inter-
ference ranging from 3.6 (relationships) to 5.5
(work) on a scale of 0 to 10. Minorities
had higher interference scores on general activity,
mood, walking, relationships, and enjoyment of
life. There were no significant gender differences in
interference.










N 96 68 (71) 28 (29)
Age (years) 56.5 57.3 54.3 0.09
% Men 33 (34) 20 (29) 13 (46) 0.11
Education
Less than high school 14 (15) 10 (15) 4 (14) 0.18
High school graduate 32 (33) 21 (31) 11 (39)
Some college 25 (26) 21 (31) 4 (14)
College graduate 25 (26) 16 (24) 9 (32)
Employment 0.41
Full time 12 (14) 7 (11) 5 (20)
Part time 7 (8) 4 (6) 3 (12)
Retired 39 (44) 27 (43) 12 (48)
Voluntarily unemployed 14 (16) 12 (19) 2 (8)
Involuntarily unemployed 16 (18) 13 (21) 3 (12)
Income 0.08
$9,999 or less 12 (13) 6 (9) 6 (22)
$10,000–$30,000 32 (34) 20 (30) 12 (44)
$30,001–$100,000 42 (45) 35 (53) 7 (26)
>$100,000 7 (8) 5 (8) 2 (7)
Marital status
Never married 8 (9) 4 (9) 4 (14) 0.002
Married 58 (62) 49 (74) 9 (32)
Divorced/separated 22 (23) 11 (17) 11 (39)
Widowed 6 (6) 2 (3) 4 (14)
Cancer type
Breast 31 (33) 24 (35) 7 (26) 0.72
Colon 14 (15) 8 (12) 6 (22)
Lung 27 (28) 20 (29) 7 (26)
Multiple myeloma 20 (21) 14 (21) 6 (22)




5 (6) 2 (3) 3 (13) 0.29
III 47 (52) 32 (50) 15 (63)
IV 38 (42) 30 (47) 8 (33)
* P  0.05.
† Differences in primary cancer stage, with white Americans more likely to
have a stage IV diagnosis and less likely to have a stage II diagnosis, may be




BTP history was required for study inclusion, but
variability in BTP characteristics was noted. On
average, subjects experienced BTP for 619 days,
with BTP duration ranging from 0 to 168 months.
There were no differences between whites and
minorities or men and women in BTP duration or
in the number of BTP episodes experienced on
average per week. Subjects attributed the precipi-
tating event for BTP to several causes (e.g., move-
ment, end-of-pain medication course), but there
were no differences by ethnicity in the frequencies
of precipitating events. Although there was great
variability within each group, there were not sig-
nificant ethnic or gender differences in the ability
to predict BTP onset. Overall, most subjects (79%)
reported BTP could be at least partially palliated
(most commonly through medications). Subjects
also reported only 62% of the BTP they experi-
enced was relieved by medication and by using
other methods for reducing BTP (e.g., lying down,
limiting movement, and heating pads). There were
not significant ethnic or gender differences in BTP
placability or in strategies used for pain relief.
BTP was higher for minorities but not signifi-
cantly different (multivariate F = 2.08; P = 0.08)
and did not differ by sex (multivariate F = 1.63;
P = 0.16). There were significant ethnicity differ-
ences on four out of five BTP subscales, with
minorities reporting significantly higher BTP
Figure 1 Consistent pain by ethnicity

































Table 2 Consistent pain, breakthrough pain, and pain interference by ethnicity and gender
White Minority Multivariate F P Men Women Multivariate F P
Consistent pain 5.49 0.001 0.29 0.880
Worst 4.71  2.93 6.57  2.44 0.004 5.34  3.17 5.21  2.79 0.839
Least 2.21  2.12 4.75  2.95 <0.001 2.81  2.91 3.03  2.53 0.705
Average 3.84  2.35 5.36  2.20 0.004 4.16  2.70 4.35  2.25 0.713
Right now 3.03  2.59 4.50  2.77 0.015 3.47  2.78 3.46  2.70 0.989
Breakthrough pain 2.08 0.08 1.63 0.163
Worst 6.93  2.23 8.11  1.83 0.018 6.90  2.66 7.52  1.85 0.210
Least 3.27  2.28 4.44  2.74 0.041 3.10  2.47 3.93  2.46 0.140
Average 4.98  2.22 5.81  2.51 0.125 4.67  2.48 5.55  2.21 0.093
Right now 2.95  2.49 4.70  2.92 0.005 3.37  2.75 3.57  2.76 0.744
Most recent 6.73  2.40 8.04  1.81 0.014 6.37  2.88 7.55  1.82 0.022
Interference 2.36 0.031 0.53 0.810
General activity 4.02  3.05 6.31  3.07 0.002 4.74  3.28 4.68  3.22 0.936
Mood 3.79  3.23 5.92  3.31 0.006 4.15  3.11 4.54  3.51 0.617
Walking ability 3.90  3.35 5.81  3.39 0.018 4.30  3.07 4.54  3.64 0.761
Work, in and out of home 5.26  3.32 6.31  3.36 0.181 5.37  3.22 5.66  3.42 0.714
Relations with others 3.03  2.84 4.85  2.60 0.014 2.93  3.14 3.85  3.17 0.208
Sleep 4.90  3.35 6.27  3.03 0.076 5.00  3.46 5.44  3.24 0.565
Enjoyment of life 4.81  3.45 6.73  2.97 0.015 5.07  3.13 5.51  3.55 0.585
* Statistically significant result (P  0.05).
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scores than whites at its worst (P = 0.02), least
(P = 0.04), when the survey was administered
(P = 0.005), and most recently (P = 0.01). Women
reported their BTP on average (P = 0.09) was
worse, and their most recent pain flare was stron-
ger (7.6 vs 6.4, P = 0.02). Figure 2 shows BTP by
ethnicity and by gender. Minorities also experi-
enced a significantly greater number of different
types of pain flares than whites (3.0 vs 1.8,
P = 0.001). Minorities experienced BTP in the
legs at a higher frequency than whites (37.5% vs
16.7%; P = 0.03), but there were not significant
differences between the two populations in the
incidence of BTP at other sites on the body or in
the total number of pain locations. There was
also great variability in BTP quality, with subjects
most commonly reporting pain that was aching
(27.9%), sharp (23.5%), or throbbing (14.7%),
although there were no ethnic or gender differ-
ences. PMI for BTP was not different by race/
ethnicity or gender.
QOL, Depression, Coping Strategies,
and Comorbidities
F values for the MANOVA tests of each set of
subscales were not significant, although when all
symptoms subscales were combined into a single
“Symptom” scale, there were trend level differ-
ences (P = 0.08) between the scores of whites and
minorities. Whites and minorities demonstrated
statistical similarities on the functioning scales of
the EORT-C. Although not statistically significant,
minorities had consistently poorer outcomes on
each subscale and had poorer functioning at a trend
level (P = 0.08) on the social functioning scale.
Minorities also reported higher average scores on
each QOL symptom control subscales than whites,
but only the pain and dyspnea symptom control
subscales demonstrated statistically significant dif-
ferences between the two groups (P = 0.05). There
were trend level differences between whites and
minorities in financial difficulty (P = 0.09). The
functioning subscales showed no gender or ethnic
Figure 2 Breakthrough pain by eth-
nicity (A) (P < 0.05 except pain at


































































differences when the function domains were com-
bined into a single “Function” scale. Table 3 shows
means and standard deviations by subgroup on the
EORTC subscales.
The subjects experienced significant psycho-
logical distress and depression when measured
with the CES-D (mean = 22.5; maximum possible
score = 60, and scores > 16 indicate depression),
but there were no differences by ethnicity or
gender. Barriers to pain treatment were not sig-
nificantly different overall (multivariate F = 1.75;
P = 0.15 by ethnicity, F = 0.67, P = 0.61 by sex),
although minorities perceived more harmful side
effects of medications than whites (P = 0.04).
All participants scored highly on the JHACS
(mean = 47.6, maximum possible score = 60), and
there were not significant ethnic differences,
although men had higher scores than women
(P = 0.03). When the subjects were asked if they
had ever been diagnosed by a physician with any
of 19 different comorbidities, there were no
ethnic or gender differences in the sum of comor-
bidities, although there was a significant differ-
ence between whites and minorities in chest pain
and angina frequency (P = 0.03) when comorbidi-
ties were examined individually. Men were more
likely to have been told they have high blood pres-
sure (P = 0.04) and there was a trend for women to
have rheumatism or arthritis more frequently
(P = 0.08).
The Relationship Between Pain and Quality of Life
Bivariate correlations between the four consistent
pain measures and the five BTP measures of the
BPI and quality of life measures showed strong
correlations (Table 4). For functioning, both con-
sistent and breakthrough pain were correlated
with general health, physical and role functioning,
and, to a lesser degree, with emotional, cognitive,
and social functioning. Both types of pain mea-
sures were also associated with all symptom scales
except diarrhea. Depression as measured by PTSD
was the only one where BTP had a more pervasive
relationship than consistent pain, yielding four
significant correlations compared with two.
Post Hoc Analysis
When whites were compared with blacks, analyses
looked nearly identical to those performed with all
racial and ethnic minorities collapsed into the
minority group.
Discussion
The existing evidence indicates ethnic and
gender disparities in the prevalence, severity, and
Table 3 Functioning and Symptoms as Measured by the EORTC
White Minority Multivariate F P Men Women Multivariate F P
EORTC functioning scales 0.62 0.71 0.99 0.43
General health 54.2  24.9 51.59  27.5 0.16 0.69 55.0  25.2 52.7  25.8 0.15 0.70
Physical 61.8  22.7 59.05  26.0 0.21 0.65 64.4  24.9 59.3  22.6 0.95 0.33
Role 49.0  28.5 46.83  32.3 0.08 0.77 47.2  30.7 49.1  28.8 0.08 0.78
Emotional 63.3  25.7 59.1  32.0 0.37 0.55 63.1  29.3 61.8  26.3 0.04 0.84
Cognitive 66.4  25.6 64.3  30.9 0.10 0.76 63.3  32.3 67.3  23.6 0.42 0.52
Social 52.3  32.8 38.1  29.4 3.13 0.08 44.4  33.4 51.2  31.9 0.85 0.36
EORTC symptom scales 0.97 0.46 0.84 0.57
Fatigue 58.8  24.1 62.7  24.4 0.48 0.49 64.3  26.3 57.3  22.6 1.81 0.18
Nausea/vomiting 22.5  27.0 24.7  30.9 0.11 0.74 24.8  31.8 22.1  25.8 0.18 0.67
Pain 54.6  25.2 66.7  25.9 4.12 0.05 55.6  28.8 59.2  24.2 0.41 0.52
Trouble sleeping 58.6  29.8 68.0  34.0 1.67 0.20 63.6  32.7 59.8  30.4 0.32 0.57
Appetite 39.9  36.1 45.3  35.8 0.41 0.52 47.5  39.1 37.9  33.9 1.49 0.23
Shortness of breath 29.8  32.1 45.3  38.3 3.81 0.05 33.3  38.2 34.5  32.4 0.02 0.88
Constipation 36.4  35.4 48.0  36.1 1.94 0.17 39.4  38.6 39.7  34.5 0.00 0.97
Diarrhea 14.7  25.6 20.0  23.6 0.83 0.37 13.1  23.5 17.8  25.9 0.74 0.39
Financial difficulties 45.3  38.8 63.0  38.5 4.02 0.05 39.6  36.4 55.9  39.9 3.75 0.06
CES-D
Depression 21.5  13.3 25.7  14.0 1.94 0.17 21.4  14.2 23.4  13.3 0.50 0.48
Barriers questionnaire 1.75 0.15 0.67 0.61
Physical 1.8  1.1 2.0  1.4 1.01 0.32 1.81  1.18 1.91  1.23 0.50 0.48
Fatalism 1.4  1.1 1.5  1.1 0.57 0.45 1.33  1.04 1.53  1.07 0.70 0.41
Communication 1.0  1.0 1.4  1.3 1.60 0.21 1.04  1.06 1.26  1.17 0.59 0.44
Harmful side effects 1.9  1.2 2.5  1.5 4.40 0.04 1.98  1.31 2.28  1.28 1.54 0.22
John Henryism active
coping
47.4  6.7 48.4  10.9 0.30 0.59 50.1  6.1 46.4  8.8 4.72 0.03
Comorbidities 2.1  1.7 2.5  2.5 0.77 0.38 2.3  2.1 2.2  1.9 0.07 0.79
EORTC = European Organisation for Research and Treatment of Cancer; CES-D = Center for Epidemiological Studies Depression Scale.
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treatment of acute, chronic, and cancer pain
[20,37–40]. Minorities may also report more
severe pain and greater pain-related interference
with daily physical and emotional functioning
[20,23,24]. Similarly, gender-based differences are
documented, with women reporting higher pre-
valence of most pain syndromes than men [41].
Barriers to treatment exist for minority popula-
tions and women even when they are assessed and
treated for pain complaints [41]. Minorities also
face structural barriers in accessing pain medica-
tions with pharmacies in predominantly minority
neighborhoods being less likely to carry adequate
supplies of prescription analgesics [28]. In addi-
tion, while Miaskowski and others did not find
disparities in the severity of cancer pain by gender,
disparities in treatment were identified [30].
However, it is important to note that Miaskowski
and others did not examine BTP [30]. Portenoy
et al. brought national attention to BTP’s impact
on QOL but did not examine ethnic or gender
variations and implications in the experience [8].
While there is compelling research demonstrating
ethnic- and gender-based disparities in acute,
chronic, and cancer pain, there is minimal infor-
mation assessing BTP characteristics and its
impact on HRQOL in an ethnically diverse popu-
lation of men and women [8,20]. To our knowl-
edge, this is one of the first to examine both ethnic
and gender differences in BTP characteristics and
HRQOL. We found that minorities experienced
significantly more consistent pain, BTP, and had
diminished QOL than whites while women expe-
rienced higher levels on some BTP measures and
less adequate pain management than men.
As previously illustrated, BTP characteristics
were highly variable. Our results confirm previous
research documenting racial and ethnic differ-
ences in consistent cancer pain with minority
populations reporting more severe consistent pain
and more pain-related interference [20]. An
important new finding is that minorities also
reported more BTP than whites. Likewise, our
findings were consistent with earlier findings
showing no gender-based disparities in consistent
cancer pain [30]. We extend the literature by
showing some BTP measures differed by gender.
However, the etiology of these ethnic and gender
differences in consistent and breakthrough pain
remains unclear. Important considerations include
clinician variability in assessing and treating pain
in these populations. This is consistent with litera-
Table 4 Correlations between pain variables and quality of life outcomes




















General health -0.22* -0.36*** -0.21* -0.34*** -0.07 -0.25* -0.23* -0.37*** -0.23*
Physical -0.43*** -0.47*** 0.46*** -0.48*** -0.22* -0.43*** -0.35*** -0.49*** -0.23*
Role -0.39*** -0.37*** -0.41*** -0.33** -0.22* -0.39*** -0.28** -0.38*** -0.28**
Emotional -0.09 -0.24* -0.12 -0.11 -0.07 -0.22* -0.17 -0.20 -0.17
Cognitive -0.16 0.18 -0.12 -0.21* -0.05 -0.17 -0.13 -0.22* -0.18
Social -0.17 0.18 -0.17 -0.26** -0.10 -0.15 -0.25* -0.31** -0.09
Symptoms
Fatigue 0.23* 0.24* 0.25* 0.29** 0.19 0.31** 0.28** 0.31** 0.20
Nausea/vomiting 0.29** 0.40*** 0.38*** 0.36*** 0.14 0.39*** 0.32 0.26* 0.13
Pain 0.66*** 0.59*** 0.64*** 0.65*** 0.46*** 0.45*** 0.50*** 0.68*** 0.53***
Trouble sleeping 0.18 0.34*** 0.26** 0.30** 0.16 0.38*** 0.19 0.29** 0.18
Appetite 0.40*** 0.35*** 0.36*** 0.40*** 0.20 0.31** 0.22* 0.35*** 0.20
Shortness of breath 0.23 0.21* 0.17 0.28** 0.17 0.24* 0.11 0.26* 0.22*
Constipation 0.27** 0.20 0.18 0.23* 0.28** 0.31** 0.23* 0.33** 0.30**
Diarrhea 0.09 0.15 0.12 0.12 0.03 0.16 0.14 0.09 0.16
Financial difficulties 0.12 0.17 0.12 0.14 0.10 0.11 0.12 0.23* 0.13
Barriers to treatment
Physiological 0.12 0.30** 0.17 0.10 -0.04 0.22* 0.20* 0.19 0.12
Fatalism 0.15 0.23* 0.25* 0.25* 0.07 0.15 0.04 0.23* 0.10
Communication 0.17 0.26* 0.15 0.24* 0.05 0.11 0.13 0.33** 0.16
Harmless effects 0.15 0.28** 0.21* 0.03 -0.02 0.16 0.07 0.12 0.09
Mental health/coping
Depression (CES-D) 0.16 0.26** 0.20* 0.16 0.17 0.30** 0.29** 0.24* 0.27**
John Henryism -0.12 0.04 -0.14 -0.12 -0.08 -0.18 -0.15 -0.14 -0.04
Comorbidities 0.21* 0.02 0.10 0.18 0.04 -0.04 -0.03 0.08 0.03
Italics P  0.10. * P  0.05; ** P  0.01; *** P  0.001.
CES-D = Center for Epidemiological Studies Depression Scale.
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ture revealing an unequal burden of pain and cli-
nician variability in decision making for all types
of pain [20,23,24]. For instance, Bernabei et al.
showed minorities are less likely to have their pain
complaints recorded in their medical chart and
received lesser quality treatment even when
assessed [27]. Clearly, clinician variability in pain
management decision making as well as structural
barriers to quality pain care is well documented
and may influence pain severity [28]. Although
examining physician decision making was not an
aim, future studies examining the prevalence of
BTP and consistent pain in diverse populations
with cancer should attempt to do so.
Beyond clinician variability, patient variability
must also be considered when interpreting our
findings [42,43]. Consistent with existing research
documenting accelerated aging in minority popu-
lations, minorities were diagnosed with breast
cancer and multiple myeloma at younger ages than
whites. Trend level ethnic differences in primary
cancer stage were also identified, with minorities
more likely to have a stage II cancer diagnosis and
less likely to have a stage IV diagnosis. These
differences were most likely due to our decision to
include multiple myeloma, the only diagnosis
where patients in stage II were recruited and a
diagnosis more frequent in minorities. Cleeland,
Anderson, and others, demonstrated in ethnically
diverse populations how patient preferences and
attitudes about cancer and pain play a significant
role in their willingness to report pain and to seek
treatment [10,11]. Our finding that minorities
reported more barriers related to medication side
effects offers another explanation for increased
pain severity. Meghani and Keane noted several
reasons for ethnic differences in medication use
for treating cancer pain, including analgesic side
effects, meaning attributed to pain, and fears of
dependency [44]. Such differences may exist by
gender and appear to differ by pain cause [45–47].
Thus, when considering cancer pain, future longi-
tudinal studies should examine BTP in a late-stage
cancer population while specifically addressing
patient preferences and attitudes in both reporting
and seeking pain care.
Another striking finding was, although few
were statistically significant, minorities reported
consistently poorer scores on all functioning and
symptom control subscales of the EORTC than
whites. The literature suggests that appropriate
pain management can lead to dramatic improve-
ments in both overall pain and HRQOL [48–50].
When consistent and breakthrough pain scores
are analyzed, our results suggest that minorities
experienced more pain. Minorities also reported
poorer QOL symptom control, with significant
differences in dyspnea control and pain control.
Ethnic differences on the pain control subscale
were also consistent with higher pain scores
reported by minorities for both consistent and
breakthrough pain. Also interesting was the
finding that, when all symptom control subscales
were combined into a single scale, there were
trend level, but not statistically significant, differ-
ences between whites and minorities. This sug-
gests that minorities do not experience the same
level of symptom control as whites do. We found
poor QOL symptom control among minorities,
consistent with literature citing disparities in pain
treatment and for other conditions as well [13].
The strong correlations found between pain and
QOL scales support this case. To our surprise, no
statistical differences were found on any QOL
functioning subscales except the social functioning
(a trend level difference), although average scores
for minorities were lower on each subscale than
for whites. Additionally, higher pain levels did not
translate to poorer functioning, and this observa-
tion deserves further study. We also observed dif-
ferences in financial difficulties in the QOL survey
consistent with lower annual household incomes
reported by minorities and by women. Future
studies should examine whether and how financial
difficulties correlate with health insurance.
Although all groups had clinically important
depressive symptoms and psychological distress
when examining psychological impairment via
the CES-D, we did not find significant ethnic or
gender differences. Consistent with the cancer lit-
erature, we observed a high prevalence of depres-
sion in our sample [1]. The literature also provides
evidence for pain causing sleep disturbance and
depression [1]. Both the cancer and the palliative
care literature provide evidence for depression as a
normal stage [51–53], while the chronic pain lit-
erature provides evidence for increased depression
and PTSD, in response to pain, in general, and for
minorities, in particular [23,24]. However, when a
patient is presenting with a cancer and a pain diag-
nosis, it is unclear whether pain causes depression,
if cancer causes depression, or if there is another
pathway yet to be examined. As all groups were
equally depressed and we did not examine whether
the subjects previously experienced clinical
depression or chronic pain, it is unclear whether
depression was a consequence of cancer or pain.
Future studies should attempt to disentangle both
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cancer and pain’s impact on depression using a
longitudinal design.
Maladaptive coping strategies diminish QOL
and the ability to cope with significant illnesses.
When James introduced the concept of John Hen-
ryism, it was strongly associated with blacks [34].
When analyzing JHACS, John Henryism was
prevalent among the entire study population,
although significantly higher among men. Explor-
atory examination did not find that John Henry-
ism moderated the relationship between gender
and the two statistically different BTP variables.
Thus, it is plausible that men used this coping
strategy for challenges posed by their cancer,
rather than dealing with consistent or BTP
syndromes. The lack of ethnic differences was sur-
prising but suggests, when faced with a life-
threatening illness, John Henryism may be a
common coping strategy among patients with
cancer regardless of race or ethnicity. As John
Henryism has primarily been studied in blacks,
until other studies addressing the validity of JHAC
in other populations are available, this must be
considered a potential study limitation. In addi-
tion, future studies should seek to confirm our
findings and to examine whether John Henryism is
an adaptive or maladaptive coping strategy when
used in an ethnically diverse population with end-
stage cancer and pain.
Although this study provides many significant
implications for improving health and QOL in
patients with cancer, there are potential limita-
tions. First, the small sample size used for data
analysis (particularly in the minority sample) may
have limited the ability to find statistical differ-
ences between whites and minorities on many
QOL measures and on comparing BTP character-
istics. It is conceivable that these differences in the
combined symptom-control scale and on indi-
vidual subscales represent differences that could
become statistically significant in a larger popula-
tion. This, in combination with the consistency of
all variables showing poorer outcomes for minori-
ties, suggests that the noted differences represent
significant disparities on a population level. These
findings further suggest the need for more study in
a larger diverse population. Second, self-report
and nonresponse bias must be considered, al-
though the surveys were completed privately and
kept confidential. In particular, those people who
were suffering most were less likely to agree to
participate in the survey because they did not feel
well. Finally, differences in incomes were noted,
although there were no education differences
noted between the minority and white samples. As
subjects were recruited through cancer care facili-
ties, our results may only reflect those with access
to care and may not be representative for those
with limited access to care.
These results have critically important implica-
tions for both clinical practice and health policy.
We showed, when treating consistent pain and
BTP, inadequate relief from pain medications for
baseline or consistent pain. We extend the litera-
ture by confirming this in ethnically diverse men
and women. Specifically, minorities experienced
significantly more symptoms than whites in BTP
severity and consistent pain severity, while women
experienced more BTP on two measures. These
findings are clinically important and significant
regardless of ethnicity or gender while pointing
toward important disparities in the quality of pain
care (i.e., pain assessment and management) influ-
encing overall health and well-being. In addition
to minorities reporting higher consistent pain and
BTP scores, they also had lower (but not signifi-
cantly different) HRQOL than whites. This study
provides new and critically important insights into
ethnic- and gender-based disparities in health,
pain care, and cancer care while serving as a novel
model for future research addressing disparities in
BTP on a population level.
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